NASDAQ:TRIV

TriVascular Technologies (TRIV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$5.87
$5.87
50-Day Range
N/A
52-Week Range
$3.98
$11.49
Volume
N/A
Average Volume
18,900 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TRIV stock logo

About TriVascular Technologies Stock (NASDAQ:TRIV)

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company's solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

TRIV Stock News Headlines

Investors Alert: The Next Big Thing in Weight Loss
UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.
World Wide Technology
Investors Alert: The Next Big Thing in Weight Loss
UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.
See More Headlines
Receive TRIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriVascular Technologies and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:TRIV
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

TRIV Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of TriVascular Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TriVascular Technologies investors own include Avinger (AVGR), Cardiovascular Systems (CSII), Edwards Lifesciences (EW), NuVasive (NUVA), Endologix (ELGX), ICU Medical (ICUI), Neovasc (NVCN), NxStage Medical (NXTM) and Orthofix Medical (OFIX).

This page (NASDAQ:TRIV) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners